Under terms of the agreement, Cipla will have exclusive rights to distribute and market Prestige’s trastuzumab biosimilar (HD201) in selected emerging markets.
Prestige Biopharma, a Singapore-based biopharmaceutical company, recently announced that it has entered into a licensing agreement with Cipla Limited. Under terms of the agreement, Cipla will have exclusive rights to distribute and market Prestige’s trastuzumab biosimilar (HD201) in selected emerging markets.
The biosimilar, referencing Roche’s Herceptin, is currently being investigated in a phase 3 study for the treatment of HER2-positive breast cancer and HER2-positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma. Prestige plans to submit the proposed biosimilar for regulatory approval with the European Medicines Agency and with the FDA in 2019.
“We are very pleased to partner with Cipla to commercialize our lead biosimilar program in selected emerging markets. With this partnership, we made another important step towards a broad global availability of our trastuzumab biosimilar product,” said Lisa Park, CEO of Prestige, in a statement.
The agreement will focus on leveraging Cipla’s strong local presence as well as sales and marketing capabilities within the local markets. Through the agreement, Prestige will be responsible for the development, product registration, and commercial supply of the biosimilar, while Cipla will be responsible for the marketing and commercialization.
“Cipla has always stood for access to life-saving medicines, and through this partnership, we take this key drug to more countries and patients around the world. We will continue to focus on capitalizing on our strengths to ensure high-quality medicines to patients in keeping with our purpose of ‘Caring for Life,’” said Umang Vohra, managing director and global CEO of Cipla.
Other products currently being developed in Prestige’s pipeline include HD204, a potential bevacizumab biosimilar currently undergoing phase 1 and 3 trials, and PBP1502, a potential adalimumab biosimilar currently in a phase 1 trial. Potential biosimilars in preclinical development include denosumab, aflibercept, eculizumab, and ipilimumab molecules.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.